Fulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. (FLGT)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss from consolidated operations | -25,274 | -23,650 | -37,981 | NaN |
| Goodwill impairment loss | NaN | 0 | NaN | NaN |
| Equity-based compensation | 9,890 | 9,276 | 30,306 | NaN |
| Depreciation and amortization | 6,000 | 6,112 | 18,011 | NaN |
| Adjustment for credit losses | 1,189 | 1,854 | 5,794 | NaN |
| Noncash lease expense | 352 | 567 | 1,197 | NaN |
| (gain) loss on disposal of fixed asset | 9 | 0 | 3 | NaN |
| Amortization of discount of marketable securities | 890 | 942 | 4,161 | NaN |
| Deferred taxes | -1,120 | -104 | -1,110 | NaN |
| Unrecognized tax benefits | -199 | -499 | -437 | NaN |
| Net realized (gain) loss on marketable securities | NaN | 41 | 21 | NaN |
| Impairment loss | NaN | 0 | 9,926 | NaN |
| Other | -1 | 4 | -34 | NaN |
| Trade accounts receivable | -16,431 | 15,377 | 7,874 | NaN |
| Income tax | -1,394 | -71,881 | -33,056 | NaN |
| Other current and long-term assets | -2,791 | -1,823 | 1,025 | NaN |
| Accounts payable | -408 | 924 | -374 | NaN |
| Contract liabilities | -627 | 1,325 | 75 | NaN |
| Customer deposits | 2,470 | -403 | 923 | NaN |
| Accrued liabilities and other liabilities | -2,123 | 12,325 | -3,414 | NaN |
| Operating lease liabilities | -381 | -446 | -1,179 | NaN |
| Net cash (used in) provided by operating activities | 7,097 | -78,143 | -23,495 | NaN |
| Maturities of marketable securities | 81,711 | 78,097 | 132,910 | NaN |
| Proceeds from sale of marketable securities | NaN | 0 | 0 | NaN |
| Proceeds from sale of fixed assets | 8 | 0 | 5 | NaN |
| Purchase of marketable securities | 10,011 | 61,963 | 18,879 | NaN |
| Purchases of fixed assets | 5,202 | 4,980 | 17,594 | NaN |
| Acquisition of businesses, net of cash | 55,567 | 0 | -3,775 | NaN |
| Net cash provided by (used in) investing activities | 10,939 | 11,154 | 100,217 | NaN |
| Repurchase of common stock | 40,078 | 0 | 10,884 | NaN |
| Common stock withholding for employee tax obligations | 4,200 | 447 | 2,589 | NaN |
| Repayment of notes payable | 476 | 0 | 471 | NaN |
| Repayment of investment margin loan | NaN | 0 | NaN | NaN |
| Principal paid for finance lease | 88 | 88 | 311 | NaN |
| Proceeds from exercise of stock options | 9 | 1 | NaN | NaN |
| Net cash used in financing activities | -44,833 | -534 | -14,255 | NaN |
| Effect of exchange rate changes on cash and cash equivalents | 3 | 75 | 30 | NaN |
| Restricted cash and cash equivalents, total | NaN | NaN | NaN | 135 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -26,794 | -67,448 | 62,497 | NaN |
| Cash and cash equivalents, at carrying value, ending balance | NaN | NaN | NaN | 87,880 |
| Cash, cash equivalents, and restricted cash at beginning of period | 50,328 | 117,776 | 88,015 | NaN |
| Cash, cash equivalents, and restricted cash at end of period | 23,534 | 50,328 | 117,776 | 88,015 |